These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 3034850)

  • 41. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers.
    Harkless L; Boghossian J; Pollak R; Caputo W; Dana A; Gray S; Wu D
    Surg Infect (Larchmt); 2005; 6(1):27-40. PubMed ID: 15865549
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A comparison of ampicillin/sulbactam and cefuroxime in the treatment of patients with bacterial infections of the lower respiratory tract.
    Geckler RW
    Clin Ther; 1994; 16(4):662-72. PubMed ID: 7982254
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Comparative study on sultamicillin and bacampicillin in the treatment of respiratory tract infections].
    Kobayashi H; Takamura K; Kono K; Nihei T; Saito A; Nakayama I; Ujiie A; Yajima O; Tango M; Tomizawa M
    Kansenshogaku Zasshi; 1985 Jul; 59(7):708-48. PubMed ID: 2997342
    [No Abstract]   [Full Text] [Related]  

  • 44. In vitro evaluations of aminopenicillin/beta-lactamase inhibitor combinations.
    Jones RN
    Drugs; 1988; 35 Suppl 7():17-26. PubMed ID: 3265377
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sulbactam/ampicillin: effects on glucose metabolism in diabetics with soft tissue infection.
    Chiodini PL; Toop MJ; Odugbesan O; Gilbert J; Farrell ID; Barnett AH; Geddes AM
    J Antimicrob Chemother; 1985 Nov; 16(5):643-7. PubMed ID: 3001015
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Activity of sulbactam/ampicillin in screening and discriminative animal models of infection.
    English AR; Girard D; Cimochowski C; Faiella J; Retsema JA; Lynch JE
    Rev Infect Dis; 1986; 8 Suppl 5():S535-42. PubMed ID: 3026002
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
    Zhao C; Xie W; Zhang W; Ye Z; Wu H
    Zhonghua Shao Shang Za Zhi; 2014 Apr; 30(2):166-70. PubMed ID: 24989663
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of four beta-lactamase inhibitors in combination with ampicillin against Mycobacterium tuberculosis.
    Sorg TB; Cynamon MH
    J Antimicrob Chemother; 1987 Jan; 19(1):59-64. PubMed ID: 3030999
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enzyme-mediated resistance to beta-lactam antibiotics: a symposium on sulbactam/ampicillin. Cairo, Egypt, April 18-19, 1985.
    Rev Infect Dis; 1986; 8 Suppl 5():S465-650. PubMed ID: 3025995
    [No Abstract]   [Full Text] [Related]  

  • 50. [Clinical studies on sulbactam/cefoperazone in the field of obstetrics and gynecology].
    Obata I; Ryu F; Imagawa N; Ochiai K; Koike K; Morimoto O; Hachiya S
    Jpn J Antibiot; 1984 Dec; 37(12):2478-94. PubMed ID: 6098741
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Worldwide clinical experience with sultamicillin.
    Pitts NE; Gilbert GS; Knirsch AK; Noguchi Y
    APMIS Suppl; 1989; 5():23-34. PubMed ID: 2660868
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antibiotic prophylaxis in transurethral surgery: a comparison of sulbactam-ampicillin and cefoxitin.
    Dørflinger T; Madsen PO
    Infection; 1985; 13(2):66-9. PubMed ID: 2987133
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Alterations in the human oropharyngeal microflora related to therapy with aztreonam, moxalactam and ampicillin plus sulbactam.
    Heimdahl A; Kager L; Nord CE
    Scand J Infect Dis; 1986; 18(1):49-52. PubMed ID: 3008310
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of ampicillin/sulbactam and sultamicillin in pediatric infections: a re-evaluation.
    Dajani A
    J Int Med Res; 2001; 29(4):257-69. PubMed ID: 11675898
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical efficacy of sulbactam/ampicillin in the treatment of moderately severe bacterial infections.
    Fong KY; Howe HS; Boey ML; Feng PH
    Singapore Med J; 1989 Apr; 30(2):170-2. PubMed ID: 2609176
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro activity against clinically important gram-positive and gram-negative bacteria of sulbactam, alone and in combination with ampicillin, cefotaxime, mezlocillin, and piperacillin.
    Schmalreck AF; Wildfeuer A
    Arzneimittelforschung; 1990 Oct; 40(10):1145-55. PubMed ID: 2291754
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ampicillin-sulbactam and ticarcillin-clavulanic acid: a comparison of their in vitro activity and review of their clinical efficacy.
    Itokazu GS; Danziger LH
    Pharmacotherapy; 1991; 11(5):382-414. PubMed ID: 1745624
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sultamicillin versus trimethoprim/sulfamethoxazole in the treatment of urinary tract infections.
    Naber KG; Wittenberger R
    APMIS Suppl; 1989; 5():57-62. PubMed ID: 2660873
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Infectious complications after 809 biliary tract operations and results of a prospective randomized single-blind study comparing cefoxitin versus ampicillin plus an inhibitor of beta-lactamases.
    Wittmann DH; Koltowski P; Oleszkiewicz J; Walker AP
    Infection; 1990; 18(1):41-7. PubMed ID: 2179137
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Sulbactam and clavulanic acid: studies of enzyme kinetics and synergism with ampicillin and mezlocillin].
    Cullmann W; Binder S; Stieglitz M
    Immun Infekt; 1987 May; 15(3):103-9. PubMed ID: 3038733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.